Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022
Description
Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022
DelveInsight’s, “Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diffuse Intrinsic Pontine Glioma: Overview
Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain's glial tissue — tissue made up of cells that help support and protect the brain's neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body's most vital functions such as breathing, blood pressure and heart rate. Approximately 300 children are diagnosed with DIPGs each year, usually between the ages of 5 and 9. Although the prognosis for DIPGs remains very poor but new research, with the help of clinical trials, may provide the key to improved treatment options. The symptoms of diffuse intrinsic pontine glioma (DIPG) usually develop very rapidly prior to diagnosis, reflecting the fast growth of these tumors. Most patients start experiencing symptoms less than three months — and often less than three weeks — before diagnosis. The most common symptoms include: rapidly developing problems controlling eye movements, facial expressions, speech, chewing, and swallowing, weakness in the arms and legs, problems with walking and coordination. The first step in treating the child is forming an accurate and complete diagnosis. Diffuse intrinsic pontine glioma (DIPG) is most commonly diagnosed from imaging studies. A number of treatments may be recommended. Some of them help to treat the tumor while others are intended to address complications of the disease or side effects of the treatment. Treatment for DIPG may include radiation therapy. DIPG falls into the Glioma staging system, so they can be classified according to the four stages below based on how the cells look under the microscope. The grades are from the least severe to the most severe. Low Grade: Grade I or II means that the tumor cells are the closest to normal. High Grade: Grade III or IV means that these are the most aggressive tumors. The main issue with DIPG is that most of these tumors are not classified by grade because surgery to obtain tissue by biopsy or to remove the tumor is not safe because of the location of the tumor. When these tumors are biopsied, they are usually grade III or grade IV tumors, which tend to behave very aggressively. Most of the tumors are diagnosed by their appearance on MRI. About 10% to 20% of all childhood brain tumors are DIPG or brainstem gliomas. They are more common in children between the ages of 5 and 10 years, but can occur at any age in childhood. Though more rare, they can also occur in adults.
""Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Intrinsic Pontine Glioma pipeline landscape is provided which includes the disease overview and Diffuse Intrinsic Pontine Glioma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Intrinsic Pontine Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Intrinsic Pontine Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diffuse Intrinsic Pontine Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Intrinsic Pontine Glioma Emerging Drugs
Further product details are provided in the report……..
Diffuse Intrinsic Pontine Glioma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Intrinsic Pontine Glioma drugs segregated based on following parameters that define the scope of the report, such as:
Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
Diffuse Intrinsic Pontine Glioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Intrinsic Pontine Glioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Intrinsic Pontine Glioma drugs.
Diffuse Intrinsic Pontine Glioma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Diffuse Intrinsic Pontine Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Diffuse Intrinsic Pontine Glioma: Overview
Diffuse intrinsic pontine gliomas (DIPGs) are highly-aggressive and difficult-to-treat brain tumors found at the base of the brain. They are glial tumors, meaning they arise from the brain's glial tissue — tissue made up of cells that help support and protect the brain's neurons. These tumors are found in an area of the brainstem called the pons, which controls many of the body's most vital functions such as breathing, blood pressure and heart rate. Approximately 300 children are diagnosed with DIPGs each year, usually between the ages of 5 and 9. Although the prognosis for DIPGs remains very poor but new research, with the help of clinical trials, may provide the key to improved treatment options. The symptoms of diffuse intrinsic pontine glioma (DIPG) usually develop very rapidly prior to diagnosis, reflecting the fast growth of these tumors. Most patients start experiencing symptoms less than three months — and often less than three weeks — before diagnosis. The most common symptoms include: rapidly developing problems controlling eye movements, facial expressions, speech, chewing, and swallowing, weakness in the arms and legs, problems with walking and coordination. The first step in treating the child is forming an accurate and complete diagnosis. Diffuse intrinsic pontine glioma (DIPG) is most commonly diagnosed from imaging studies. A number of treatments may be recommended. Some of them help to treat the tumor while others are intended to address complications of the disease or side effects of the treatment. Treatment for DIPG may include radiation therapy. DIPG falls into the Glioma staging system, so they can be classified according to the four stages below based on how the cells look under the microscope. The grades are from the least severe to the most severe. Low Grade: Grade I or II means that the tumor cells are the closest to normal. High Grade: Grade III or IV means that these are the most aggressive tumors. The main issue with DIPG is that most of these tumors are not classified by grade because surgery to obtain tissue by biopsy or to remove the tumor is not safe because of the location of the tumor. When these tumors are biopsied, they are usually grade III or grade IV tumors, which tend to behave very aggressively. Most of the tumors are diagnosed by their appearance on MRI. About 10% to 20% of all childhood brain tumors are DIPG or brainstem gliomas. They are more common in children between the ages of 5 and 10 years, but can occur at any age in childhood. Though more rare, they can also occur in adults.
""Diffuse Intrinsic Pontine Glioma- Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diffuse Intrinsic Pontine Glioma pipeline landscape is provided which includes the disease overview and Diffuse Intrinsic Pontine Glioma treatment guidelines. The assessment part of the report embraces, in depth Diffuse Intrinsic Pontine Glioma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diffuse Intrinsic Pontine Glioma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Intrinsic Pontine Glioma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Intrinsic Pontine Glioma.
This segment of the Diffuse Intrinsic Pontine Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Intrinsic Pontine Glioma Emerging Drugs
- MTX 110: Midatech
- Paxalisib: Kazia Therapeutics
Further product details are provided in the report……..
Diffuse Intrinsic Pontine Glioma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Intrinsic Pontine Glioma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diffuse Intrinsic Pontine Glioma
Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Diffuse Intrinsic Pontine Glioma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Intrinsic Pontine Glioma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Intrinsic Pontine Glioma drugs.
Diffuse Intrinsic Pontine Glioma Report Insights
- Diffuse Intrinsic Pontine Glioma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diffuse Intrinsic Pontine Glioma drugs?
- How many Diffuse Intrinsic Pontine Glioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Intrinsic Pontine Glioma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Intrinsic Pontine Glioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diffuse Intrinsic Pontine Glioma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Midatech
- Kazia Therapeutics
- Kintara Therapeutics
- Oncotelic Therapeutics
- Antisense Pharma
- Y-mAbs Therapeutics
- PTC Therapeutics
- Celgene Corporation
- MTX 110
- Paxalisib
- Trabedersen
- VAL-083
- Omburtamab I-124
- BXQ-350
- AloCELYVIR
- PTC-596
- Marizomib
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Diffuse Intrinsic Pontine Glioma: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diffuse Intrinsic Pontine Glioma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/II)
- Comparative Analysis
- MTX 110: Midatech
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diffuse Intrinsic Pontine Glioma Key Companies
- Diffuse Intrinsic Pontine Glioma Key Products
- Diffuse Intrinsic Pontine Glioma- Unmet Needs
- Diffuse Intrinsic Pontine Glioma- Market Drivers and Barriers
- Diffuse Intrinsic Pontine Glioma- Future Perspectives and Conclusion
- Diffuse Intrinsic Pontine Glioma Analyst Views
- Diffuse Intrinsic Pontine Glioma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
